PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy
Cell Metabolism · 2023-03 · 35 (3) · 517-534.e8
DOI: 10.1016/j.cmet.2023.01.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Metabolism, 2023-03. Verfasst von Duo Zhang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Glioblastoma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 145-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
The efficacy of immunotherapy is limited by the paucity of T cells delivered and infiltrated into the tumors through aberrant tumor vasculature. Here, we report that phosphoglycerate dehydrogenase (PHGDH)-mediated endothelial cell (EC) metabolism fuels the formation of a hypoxic and immune-hostile vascular microenvironment, driving glioblastoma (GBM) resistance to chimeric antigen receptor (CAR)-T cell immunotherapy. Our metabolome and transcriptome analyses of human and mouse GBM tumors identify that PHGDH expression and serine metabolism are preferentially altered in tumor ECs. Tumor microenvironmental cues induce ATF4-mediated PHGDH expression in ECs, triggering a redox-dependent mechanism that regulates endothelial glycolysis and leads to EC overgrowth. Genetic PHGDH ablation in ECs prunes over-sprouting vasculature, abrogates intratumoral hypoxia, and improves T cell infiltration into the tumors. PHGDH inhibition activates anti-tumor T cell immunity and sensitizes GBM to CAR T therapy. Thus, reprogramming endothelial metabolism by targeting PHGDH may offer a unique opportunity to improve T cell-based immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.
- Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Pathology, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NINDS NIH HHS
- American Heart Association
- National Institutes of Health
- American Cancer Society
- NCI
- NINDS
Zitieren
APA
Zhang, D., Li, A. M., Hu, G., Huang, M., Yang, F., Zhang, L., Wellen, K. E., Xu, X., Conn, C. S., Zou, W., Kahn, M., Rhoades, S. D., Weljie, A. M., Fuchs, S. Y., Amankulor, N., Yoshor, D., Ye, J., Koumenis, C., Gong, Y., & Fan, Y. (2023). PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. Cell Metabolism, 35(3), 517-534.e8. https://doi.org/10.1016/j.cmet.2023.01.010
Vancouver
Zhang D, Li AM, Hu G, Huang M, Yang F, Zhang L, et al. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. Cell Metabolism. 2023;35(3):517-534.e8. doi:10.1016/j.cmet.2023.01.010
BibTeX
@article{Zhang2023,
author = {Zhang, Duo and Li, Albert M and Hu, Guanghui and Huang, Menggui and Yang, Fan and Zhang, Lin and Wellen, Kathryn E and Xu, Xiaowei and Conn, Crystal S and Zou, Wei and Kahn, Mark and Rhoades, Seth D and Weljie, Aalim M and Fuchs, Serge Y and Amankulor, Nduka and Yoshor, Daniel and Ye, Jiangbin and Koumenis, Constantinos and Gong, Yanqing and Fan, Yi},
title = {PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy},
journal = {Cell Metabolism},
year = {2023},
volume = {35},
number = {3},
pages = {517--534.e8},
doi = {10.1016/j.cmet.2023.01.010}
}
EUVIMED